Regulatory Reform

Business

CoreWeave's High-Stakes Balancing Act: Nvidia's $2B Bet Meets Investor Lawsuits

AI infrastructure provider CoreWeave finds itself at a critical juncture, buoyed by a deepened $2 billion partnership with chip giant Nvidia while simultaneously defending against securities lawsuits. Investors are weighing the promise of accelerated growth against allegations of misleading disclosures, creating a volatile mix for the high-flying stock.

Feb 2, 2026

Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Feb 2, 2026

Business

KPJ Healthcare Berhad Sees Accelerating Returns on Capital, Signaling Strategic Growth

The Malaysian healthcare provider KPJ Healthcare Berhad is demonstrating a strengthened capacity for profitable reinvestment, with its return on capital employed rising to 11% alongside significant capital expansion, pointing to a robust operational model.

Feb 2, 2026

World

Asahi Poll Predicts Landslide Victory for PM Takaichi's LDP in Upcoming Election

A new poll indicates Prime Minister Sanae Takaichi's ruling coalition is on track for a decisive win in next week's lower house election, potentially strengthening her mandate for expansive fiscal policies.

Feb 2, 2026

Business

Glaukos Gains FDA Nod for Repeat iDose TR Implant, Bolstering Its Long-Term Glaucoma Platform Strategy

The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.

Feb 2, 2026

Business

Archer Aviation Lands Strategic Deal with Serbia, Eyes European eVTOL Market Ahead of EXPO 2027

Archer Aviation secures a pivotal agreement with Serbia to supply its electric air taxis for EXPO 2027, marking a significant step into the European market and sparking discussions on its path to commercialization and valuation.

Feb 2, 2026

Business

Apple's Valuation Crossroads: Is the Tech Giant Overpriced or a Hidden Bargain?

As Apple's stock experiences recent volatility, investors are grappling with a critical question: does its current price reflect its long-term potential? A deep dive into valuation models reveals a complex picture, with traditional metrics painting conflicting signals about the iPhone maker's true worth.

Feb 2, 2026

Business

BeOne Medicines: A Valuation Check Amidst Volatile Trading and Long-Term Promise

BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.

Feb 2, 2026

Business

Circle's Arc Blockchain Gains Traction with Intuit Deal and Federal Banking Approval

Circle Internet Group (NYSE: CRCL) unveils a strategic 2026 roadmap for its Arc blockchain, secures a landmark partnership with Intuit, and receives conditional approval to establish a federally supervised digital currency bank, signaling a major push to bridge crypto and traditional finance.

Feb 2, 2026

Business

First American Financial Maintains Dividend Amid Board Transition as Stock Holds Steady

First American Financial Corp. announces the retirement of director Martha Wyrsch while reaffirming its quarterly dividend, signaling stability in shareholder returns during a period of governance change. The company's stock performance and capital allocation strategy remain in focus for investors.

Feb 2, 2026

Business

Enterprise Products Pivots: From Growth Spree to Shareholder Returns

After years of heavy investment in organic growth, midstream giant Enterprise Products Partners signals a strategic shift, slashing future capital expenditures and ramping up buybacks to return more cash to investors.

Feb 2, 2026

Business

Seabridge Gold Advances KSM Development, Announces Strategic Spin-Out of Valor Gold

Seabridge Gold reports significant on-site progress at its flagship KSM project while unveiling plans to spin out its Courageous Lake asset into a new publicly traded company, Valor Gold, distributing shares to existing shareholders.

Feb 2, 2026

Business

Davos Clash: Jamie Dimon's Heated Confrontation with Coinbase CEO Exposes Deep Rift Over Crypto's Future

A reported fiery exchange between JPMorgan's Jamie Dimon and Coinbase's Brian Armstrong at the World Economic Forum lays bare the intensifying battle between traditional finance and the crypto industry over regulation, deposits, and the future of money.

Feb 2, 2026

Business

Tanager Wealth Exits $14.5M Centessa Stake After Biotech's Stellar Run

Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.

Feb 2, 2026

Business

Trump's Second Term: A Windfall for Tech Titans as Musk, Bezos, Zuckerberg Add Billions

An analysis of wealth accumulation among the world's top billionaires reveals staggering gains during the current presidential term, with policy and market dynamics fueling unprecedented fortunes.

Feb 2, 2026

Business

Pinterest Announces Workforce Restructuring, Doubling Down on AI Amid User Backlash Over 'Synthetic' Content

The visual discovery platform Pinterest is cutting up to 15% of its global workforce as part of a strategic shift toward AI development, a move that has reignited concerns among its user base about the proliferation of AI-generated images flooding the platform.

Feb 2, 2026

Business

Sarepta's Gene Therapy Shows Sustained Slowing of DMD Progression in Landmark Three-Year Data

New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.

Jan 31, 2026

Business

Definium Therapeutics Bolsters Board with Commercial Veteran Roger Adsett Ahead of Pivotal Trials

Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.

Jan 31, 2026

Business

Greenlight Capital Bets Big on New Coal Giant Core Natural Resources Post-Merger

Greenlight Capital has spotlighted Core Natural Resources (CNR), the entity formed from the merger of Arch Resources and CONSOL Energy, as a key coal investment. The fund cites the company's valuation and combined asset base, even as the sector grapples with operational challenges. This endorsement brings renewed scrutiny to CNR's integration path and its strategy in a complex market.

Jan 31, 2026

Business

U.S. Bets Big on Rare Earth Independence with $3.1 Billion Mine-to-Magnet Push

USA Rare Earth secures a landmark $1.6 billion in federal loans and equity, coupled with a $1.5 billion private placement, to build a domestic supply chain from Texas mines to Oklahoma magnets, reducing reliance on China for critical defense and green tech components.

Jan 31, 2026